Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 3,076 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $266.39, for a total value of $819,415.64. Following the completion of the transaction, the chief executive officer directly owned 99,897 shares in the company, valued at $26,611,561.83. This represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Steven Leonard Chapman also recently made the following trade(s):
- On Tuesday, July 28th, Steven Leonard Chapman sold 3,580 shares of Natera stock. The shares were sold at an average price of $254.07, for a total value of $909,570.60.
- On Monday, July 27th, Steven Leonard Chapman sold 2,190 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $570,473.10.
- On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72.
Natera Stock Down 0.2%
Shares of NTRA stock opened at $274.58 on Thursday. The firm has a 50 day moving average of $251.03 and a 200-day moving average of $222.85. The company has a market cap of $39.32 billion, a price-to-earnings ratio of -168.45 and a beta of 1.51. Natera, Inc. has a 52 week low of $135.75 and a 52 week high of $288.04.
Key Natera News
- Positive Sentiment: Natera filed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of its Signatera test for bladder cancer. Approval would expand the addressable market for the company’s molecular residual disease testing and could support additional international revenue growth. Natera Files for Japan PMDA Approval of Signatera Test in Bladder Cancer
- Neutral Sentiment: Natera reported sales by CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and executives Solomon Moshkevich and John Fesko totaling approximately 7,576 shares and $2.02 million. Each sale was executed under a pre-arranged Rule 10b5-1 plan and was made to cover tax withholding obligations from vested equity awards. The executives retained substantial positions, reducing the significance of the transactions as a signal of weakening confidence.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the stock. BTIG Research set a $275.00 price target on shares of Natera and gave the company a “buy” rating in a research note on Wednesday, June 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Natera in a research report on Monday, July 6th. Sanford C. Bernstein began coverage on Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 price target on the stock. Finally, Royal Bank Of Canada started coverage on Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average price target of $267.83.
Read Our Latest Report on NTRA
Institutional Trading of Natera
Institutional investors and hedge funds have recently modified their holdings of the stock. Coatue Management LLC boosted its position in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP raised its position in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the last quarter. Norges Bank bought a new position in Natera during the 4th quarter valued at $372,398,000. JPMorgan Chase & Co. lifted its stake in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Natera by 39.0% during the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after acquiring an additional 673,315 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
